64th ASH Annual Meeting and Exposition: 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders I

Symposia: Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological Oral and Poster Abstracts
Oral

clinical trials, Research, bleeding disorders, adult, Bleeding and Clotting, Biological therapies, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, hemophilia, epidemiology, elderly, Clinical Research, health outcomes research, pediatric, Diversity, Equity, and Inclusion (DEI) , Diseases, neonatal, Therapies, real-world evidence, registries, Adverse Events, Infusion, young adult , Human, Study Population, Maternal Health

271-273 (Ernest N. Morial Convention Center)

Moderators:

Craig D. Seaman, University of Pittsburgh and Hemophilia Center of Western Pennsylvania and Chittalsinh M Raulji, MBBS,

Disclosures:

Seaman: Novo Nordisk: Honoraria; Sanofi: Honoraria; HEMA Biologics: Honoraria; Takeda Pharmaceuticals: Honoraria; Genentech: Honoraria. Raulji: Sanofi Genzyme: Other: Single Advisory Board for the company.

What are we in the bleeding disorders community able to learn from the data that our patients contribute to the datasets and registries? The data re now maturing, and we can now begin to answer the questions we and our patients have been asking about the best ways to deliver their care. Which products? When? To whom?

9:30 AM

Incidence of Inhibitors in Previously Untreated Patients with Severe Hemophilia a Treated with Plasma-Derived Vs. Recombinant Factor VIII Concentrates: A Systematic Review and Meta-Analyses

Alessandra N L Prezotti, MD^1,2^*, Paula Ribeiro Villaça, MD, PhD³^*, Debora M C Rocha⁴^*, Maria P S V Orletti⁴^*, Christiane Lourenço, PhD⁴^*, Gabriela G Yamaguti Hayakawa, MD^1,5^* and Margareth C Ozelo, MD, PhD^1,5

¹Department of Internal Medicine, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, SP, Brazil
²Hemocentro do Espirito Santo, HEMOES, Vitoria, Brazil
³Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, SP, Brazil
⁴Hemocentro do Espirito Santo, HEMOES, Vitória, ES, Brazil
⁵Hemocentro UNICAMP, University of Campinas, Campinas, SP, Brazil

9:45 AM

Characterization of Bleeding and Laboratory Phenotype of Carriers of Hemophilia and Trends of Utilization of Factor Concentrates and Hemostatic Therapies: Analysis of the National Athndataset

Neeraja Swaminathan, MD¹, Brian Hu, MS, PhD²^*, Alison Currie³^*, Roshni Kulkarni, MD⁴, Steven W. Pipe, MD⁵, Michael Recht, MD, PhD, MBA⁶, Peter A. Kouides, MD⁷ and Anjali Sharathkumar, MD, MS⁸

¹Vanderbilt University Medical Center, Nashville, TN
²American Thrombosis and Hemostasis Network, Rochester, NY
³Stead Family Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA
⁴Center for Bleeding and Clotting Disorders, Michigan State University, East Lansing, MI
⁵University of Michigan, Ann Arbor, MI
⁶Oregon Health and Science University, Portland, OR
⁷Department of Medicine, Mary M. Gooley Hemophilia Center, Rochester, NY
⁸Carver College of Medicine, University of Iowa, Iowa City, IA

10:00 AM

Characteristics and Bleeding Behavior of Females with Mild Hemophilia A: Longitudinal Study from Picnichealth Hemophilia A Database

Angela C. Weyand, MD¹, Hwai Jing Hiew, MD, FRCPath^2,3^*, Yanrong Jiang, MBBS, MRCP^3,4^*, Athanasios Siadimas, MSc⁵^*, Francis Nissen, MD, PhD⁵^*, Gillian Hanson, ND⁶^*, Emily Cibelli, PhD⁶^*, Katya Moreno, MD⁵^*, Hanlu Zhang, MSc⁵^* and Anjali Sharathkumar, MD, MS⁷

¹University of Michigan, Ann Arbor, MI
²University Hospital Southampton NHS Trust, Southampton, ENG, United Kingdom
³Roche Products Ltd., Welwyn Garden City, United Kingdom
⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
⁵F. Hoffmann-La Roche Ltd., Basel, Switzerland
⁶PicnicHealth, San Francisco, CA
⁷Carver College of Medicine, University of Iowa, Iowa City, IA

10:15 AM

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Shannon L Carpenter, MD, MS¹, Martin Chandler, BS²^*, Michael F Guerrera, MD³, Lynn Malec, MD⁴, Matthew Manuel, MS, PhD²^*, Michael Recht, MD, PhD, MBA⁵, Ulrike Reiss, MD⁶, Robert F. Sidonio, Jr., MD, MSc⁷, Cristina Tarango, MD⁸, Marijke Van den Berg, MD, PhD⁹, Michael Wang, MD¹⁰ and Courtney D. Thornburg, MD¹¹

¹Children's Mercy Hospital, Kansas City, MO
²American Thrombosis and Hemostasis Network, Rochester, NY
³Children's National Hospital, Washington, DC
⁴Versiti BloodCenter of Wisconsin, Milwaukee, WI
⁵Yale University School of Medicine, New Haven, CT
⁶Department of Surgery, St. Jude Children's Rsch. Hosp., Memphis, TN
⁷Aflac Cancer and Blood Disorders Center, Emory University, Decatur, GA
⁸Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
⁹Blood Center of Wisconsin, Madison
¹⁰Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO
¹¹Rady Children's Hospital, San Diego, CA

10:30 AM

Mortality Trends Among Persons with Hemophilia in the United States, 2000-2021

Amanda B Payne, PhD, MPH¹, Binh Le, MD, MPH²^*, Meredith A Oakley, DVM, MPH²^*, Brandi Dupervil, DHSc, MPH²^*, Marilyn J Manco-Johnson, MD³, Anjali Sharathkumar, MD, MS⁴, Stacy E. Croteau, MD^5,6, Rajiv K. Pruthi, M.B.B.S⁷, Skye J Peltier, MPH, PA-C⁸^*, Norma Wolf, MBA, MSN, RN⁸^*, Roshni Kulkarni, MD⁹ and Vanessa R Byams, DrPH, MPH²^*

¹National Center on Birth Defects and Developmental Disabilities, Centers For Disease Control and Prevention, Atlanta, GA
²National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
³Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO
⁴Carver College of Medicine, University of Iowa, Iowa City, IA
⁵Boston Children's Hospital, Boston, MA
⁶Boston Hemophilia Center, Boston, MA
⁷Division of Hematology, Mayo Clinic, Rochester, MN
⁸American Thrombosis & Hemostasis Network, Rochester, NY
⁹Center for Bleeding and Clotting Disorders, Michigan State University, East Lansing, MI

10:45 AM

Clinical and Treatment Characteristics of Infants and Toddlers Less Than Two Years of Age with Hemophilia: A Report from the Community Counts Registry

Jennifer H. Han, MD¹^*, Brandi Dupervil, DHSc, MPH²^*, Roshni Kulkarni^3,4, Arash Mahajerin⁵ and Courtney D. Thornburg, MD^6,7

¹Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
²National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
³Center for Bleeding and Clotting Disorders, Michigan State University, East Lansing, MI
⁴Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI
⁵Children's Hospital of Orange County, Orange, CA
⁶Department of Pediatrics, UC San Diego Health Sciences, La Jolla, CA
⁷Hemophilia and Thrombosis Treatment Center, Rady Children’s Hospital San Diego, San Diego, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

322.O2.6 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders I